INTRODUCTION
West Nile virus (WNV; family Flaviviridae; genus Flavivirus), a group of mosquito-borne zoonotic flaviviruses, historically has been distributed around parts of Africa, Eurasia and Australia. Since 1999, WNV has invaded the Western Hemisphere and it is thought that this lineage originated from the eastern Mediterranean basin (Lanciotti et al., 1999; Zeller & Schuffenecker, 2004) . WNV and related flaviviruses typically cause asymptomatic infections, fever and neurological disease. In the North American human population, 80 % of WNV cases are asymptomatic and~1-2 % of infections result in neurological manifestations, with a high annulirostris mosquito pools (Doherty et al., 1963) . Serological surveys and experimental infection studies indicated that the natural vertebrate hosts are birds of the family Ardeidae (herons, night herons and egrets) (Boyle et al., 1983) . WNV-KUNV is endemic in northern tropical Australia and extends into the southern regions of the continent only after seasons of high summer rainfall. Only small numbers of human clinical cases of WNV-KUNV have been reported; none has been fatal and most have fully regained neurological function (Gray et al., 2011 (Gray et al., , 2012 Hall et al., 2002; Phillips et al., 1992) . For 23 recorded cases, signs included encephalitic and meningitic presentations, fever, headache, rash, arthralgia and myalgia, lethargy and photophobia (Gray et al., 2011 (Gray et al., , 2012 Hall et al., 2002) . Around 10 % of cases with neurological disease had residual signs, including muscle weakness, vertigo, palsy and unsteady gait (Gray et al., 2011 (Gray et al., , 2012 Hall et al., 2002; Mackenzie et al., 1993) . Many more cases may go unrecognized due to restricted case definitions and serological cross-reactivity with related flaviviruses (Hall et al., 2002) . Whereas WNV-KUNV disease affects a range of ages, North American WNV appears to cause severe disease mainly in elderly people and people with underlying medical conditions (Guarner et al., 2004; Hayes & Gubler, 2006; O'Leary et al., 2004) . Apart from humans, WNV-KUNV also causes disease in horses. Prior to 2011, WNV-KUNV was reported only in two horses with neurological disease in Victoria (Badman et al., 1984) . During the autumn of 2011, WNV-KUNV was associated with a large number of neurological cases in horses in south-east Australia (Frost et al., 2012; Mann et al., 2013; Roche et al., 2013) and this outbreak evidently did not extend to humans (Williams et al., 2013) .
West Nile disease prevalence is highly variable across geographical areas of its distribution, but the reasons for this are not understood clearly. For example, WNV is one of the principal causes of encephalitis in North America, but in Australia, disease caused by WNV-KUNV is rare. This may be partially due to differences in virus frequency and in human population densities in endemic areas. It may also be caused by variations in pathogenicity. North American variants have a mouse LD 50 of~1 p.f.u., whereas the LD 50 of the WNV-KUNV proto-strain (MRM16) was .10 000 p.f.u., and other WNV isolates from Africa and Eurasia fall within this spectrum (Beasley et al., 2004) . However, this relationship needs to be substantiated, as other studies have shown that other strains of WNV-KUNV are pathogenic to mice (Frost et al., 2012) . As long as the determinants of pathogenicity are understood poorly, the threat that mild WNV types may evolve to become more pathogenc will remain unquantifiable. In addition, viruses will be transported around the world, and in the Australian context, it is crucial that new variants can be quickly and reliably distinguished from endemic variants with regard to the risks they pose.
Infection with WNV and other neurotropic flaviviruses is thought to start in keratinocytes and cutaneous Langerhans cells around the site of the mosquito bite (Lim et al., 2011) . Infection is carried via the lymphatic system into the bloodstream, leading to systemic viral replication (Malkova & Frankova, 1959) and infection of the brain (Huang & Wong, 1963) . For flaviviruses, viral entry into the central nervous system (CNS) is thought to be mainly via the blood-brain barrier (King et al., 2007) . Retrograde axonal transport has been demonstrated as a possible route of entry into the CNS (Samuel et al., 2007) , although the role of this mechanism is unclear. The mechanisms behind pathogenicity, as determined in mouse models, have a strong immunological component, as low pathogenic variants are unable to evade IFN-1 pathways in the way that more pathogenic variants are able to do (Daffis et al., 2011; Diamond, 2009; Liu et al., 2006) .
It is important that refined tools, including a relevant animal model, be developed for assessing risk of WNV for species of interest, particularly humans and horses. The aim of this study was to characterize WNV disease in a mouse model and to elucidate the pathogenetic features that determine disease variation. This will help to validate the model for humans and horse infection, and reveal the molecular and morphological mechanisms of pathogenicity, which in turn may allow us better risk predictions of emerging variants. We used an established method for testing the pathogenicity of these viruses: inoculation of varying dilutions of virus by the intraperitoneal route in 3-week-old Swiss mice (Beasley et al., 2004) . In our extended version of the model, we classified disease outcomes by developing a scoring system for a range of metrics, including incubation period, clinical and pathological signs, tissue tropism of virus, and serological data, to determine phenotypic differences between the viruses. Our results provided insights into the pathogenetic mechanisms for WNV and the morphological determinants of pathogenicity.
RESULTS

All tested WNVs caused disease in mice
Varying 10-fold dilutions of five WNV strains were inoculated into groups of five mice by the intraperitoneal route. The earliest signs of disease appeared 5 days postinoculation (p.i.). Fifty-two mice with clinical signs were euthanized for welfare reasons from 5 to 9 days p.i. Seven mice were found dead from 7 to 12 days p.i. The remainder (61 mice, including five PBS-inoculated controls) survived to 14 days p.i. and were euthanized in good health at the termination of the trial.
Clinical signs in the mice included: inability to move the limbs, including flaccid paralysis and tonic spasms of the back and leg muscles; seizures, twitching and tremors; imbalance; scratching, particularly of the head and face; slow, reduced activity; hunched posture with short shuffling gait; ruffled fur; weight loss; mild to marked swelling of the abdomen; diarrhoea, with matting of faeces around the perineum; and mild swelling of the muzzle. Tonic spasms occurred on stimulation, usually when opening the cage, and was presented as transient dragging of the hind limbs.
The number and percentage of mice showing signs in the different groups is presented in Table 1 .
Apart from four mice that had minor weight loss in the first 2 days after inoculation (possibly associated with weaning), all mice consistently showed weight gains at the day of inoculation and for each day until clinical disease appeared (mean weight gain of 8.2-9.5 % per day). All clinically affected mice showed weight loss of between 1.1 and 25.1 % (mean 11.2 %, SD 5.24) of their maximum weight in the period between peak weight and euthanasia. The large majority of clinically affected cases were euthanized 1 (55.9 %) or 2 (40.7 %) days after their maximum weight.
The majority of clinically affected mice did not have any visible abnormalities on necropsy. Signs in the small number that did included red peritoneal fluid and swollen intestines distended with liquid ingesta.
Disease prevalence for the different strains of WNV is variable
We wished to demonstrate in mice that infection with the selected strains would reflect a wide range of infectivity and pathogenicity, as this is the pattern seen in human and horse populations, and to determine the influence of viral dose on these measures. Here, we use the term infectivity as the ability of the virus to cause infection, as measured by disease or seroconversion, while pathogenicity is the ability of the virus to cause disease. WNV NY99 was the most infective and pathogenic of the five viruses ( Table 2 ). The WNV-KUNV viruses were of similar infectivity; although no end point (a dilution group with 100 % negative) was reached for WNV , it appears to be comparable with the other WNV-KUNV strains. With WNV NY99 , all infected mice developed disease, only 29 % of mice with WNV KUNV-MRM16 developed disease, whilst 85-94 % of the mice infected with the horse isolates developed disease (Table 2 ). It is apparent that whilst infectivity is clearly dose-related, the association of dose with pathogenicity is not as clear; this is most apparent from the disease series of WNV and, to a lesser extent, the series for the horse isolates. For this reason, a median disease-causing dose was not calculated as it was considered invalid.
Dose does not have an influence on disease presentation
We compared disease metrics across dose groups of a virus. We found that there were no clear trends in disease presentation (clinical and pathological signs, tissue tropism) across challenge dose groups of a virus. However, there was a slight inverse trend between dose and the interval between challenge and peak weight and between challenge and death. The absence of clear dose effects on disease presentation would support the notion that dose, whilst influencing the development or absence of infection and the length of the incubation period, does not influence disease type or severity of outcome. The absence of dose effects allowed us to treat diseased mice as a uniform group for comparison of virus treatment effects.
WNV disease is mainly, but not exclusively, neurological
We then wished to confirm that disease caused by WNV is neurological, through infection of the CNS and peripheral Further information on antigen scores is given in Table 3 . *The weight taken at euthanasia, as a percentage of the maximum recorded weight of the mouse. DNeurological signs were the number of mice with either paralysis or seizures or both.
nervous system. Tissues from the mice were examined microscopically. The most common microscopic abnormality was non-suppurative meningoencephalitis and myelitis, shown by the presence of mononuclear cells within the meninges and around the blood vessels, and mild-to-moderate diffuse oedema and gliosis. There was also focal degeneration and neuronal necrosis within brain parenchyma. In many mice, there was intestinal stasis as shown by abnormally large boli of ingesta within the small intestine. As discussed below, this is probably secondary to infection of the enteric nervous system. A common non-neural lesion was necrosis of the odontoblastic and ameloblastic cells and periodontal connective tissues of the developing teeth.
WNV replication takes place mainly in neural tissue
We conducted comprehensive immunohistochemical analysis of the mouse tissues sets to determine where viral replication was taking place. Tissues of the mice that showed clinical signs of disease or that survived with seroconversion were stained with an immunohistochemistry procedure to detect viral non-structural protein 1 (NS1) antigen. Mice that belonged to the negative control group were stained also; no antigen staining was detected in this group.
In infected mice, viral antigen was detected in neuron cell bodies of the brain (Fig. 1a) , spinal cord ( Fig. 1b ) and ganglia, with smaller amounts in neuropil and ganglia of cranial and spinal nerves. No antigen was detected in peripheral nerve fibres. Antigen was distributed widely in the neuron cell bodes of the enteric nervous system, these being particularly prominent in the large intestine (Fig. 1c) . These findings confirm that WNV is neurotropic in mice, particularly for nerve cell bodies, including those of the enteric nervous system.
The distribution and amount of viral antigen in neural tissue varied by virus. Generally, mice infected with WNV NY99 had greater amounts of viral antigen in brain, spinal cord and enteric nerve cell bodies, whilst these levels were lowest in WNV KUNV-MRM16 -infected mice and intermediate in mice infected with the horse isolates ( Fig. 2) . Generally, WNV NY99 caused consistently large amounts of viral antigen in nervous tissues, whereas for WNV-KUNV the antigen quantities and prevalence were more variable, but generally lower than for WNV NY99 .
WNV also replicates in non-neural tissues
In non-neural tissues, antigen was seen in the odontoblastic and ameloblastic layers and periodontal connective tissue lesions of the developing teeth ( Fig. 1d ), in the smooth muscle of blood vessel walls (Fig. 1e, f) , in other connective tissue (principally periosteum), in individual cardiac muscle cells and skeletal myocytes, in small foci in bone marrow, in kidney tubular epithelium, and in pancreatic interstitium and epithelium.
The distribution of viral antigen in non-neural tissue varied by virus even more distinctly that it did in neural tissue. In WNV NY99 -infected mice, viral antigen was found in nonneural tissues in all cases, whereas antigen in mice infected with WNV-KUNV was rarely seen in non-neural tissues (Table 3 , Fig. 3 ).
We did not detect any viraemia during the acute disease stage, as terminal serum samples were negative for virus after culture on Vero cells.
WNV disease can be classified into pathological groups ('pathotypes')
Hierarchical cluster analysis was used on the various metrics of disease recorded and the resulting dendrogram classified the infected cases (diseased or healthy/seroconverted) into four separate disease groups (Fig. 4) . The groups classified the cases by pathology and although there was no clear correlation of group with viral strain, there were definite trends in the strain proportions that made up the groups. The major distinction was between those mice that seroconverted and survived to the end of the trial, consisting mainly of mice with WNV KUNV-MRM16 (Group 1) and those that developed disease. Within those groups that showed disease and were euthanized before the trial termination, one group (Group 2) contained cases with mild signs (none had neurological signs, all had hunched posture or distended abdomen, and nearly all had no inflammation and no antigen in spinal cord and extra-neural tissues). One group (Group 4) had severe signs (all had paralysis and encephalitis, and high antigen scores for brain) and a large proportion of these were mice infected with WNV NY99 . 
DISCUSSION
Australian variants of WNV rarely cause disease and the study of them may shed light on the factors that determine pathogenicity of these important neurotropic viruses. In this study, our aim was to characterize WNV disease in a mouse model. Although mouse infection models have been used to characterize the pathogenicity of WNVs previously (Beasley et al., 2004; Donadieu et al., 2013; Frost et al., 2012) , these have relied on lethality as the primary metric of disease. Our approach extends this model by introducing a comprehensive analysis of the various metrics of disease to allow a more precise classification of viral pathotype. Although no viral strain was characterized by a single clinical sign or pathological finding, the analysis helped to define those metrics, such as extra-neural viral antigen, that are important for distinguishing pathotype. The methods described in this paper may be useful for distinguishing subtle differences in pathogenicity between closely related flaviviruses or for distinguishing the significance of amino acid sequence differences in recombinant viral clones.
In this study, we used an established mouse infection model, with similar route of inoculation and animal age, but extended it by introducing the analysis of metrics by which to evaluate the disease outcome. It is likely that different host features (such as age) and inoculation route may produce different outcomes, and this will be evaluated in future studies. Nevertheless, the model indicated that pathotypic variation can be detected and evaluated for flaviviruses.
Our study in mice showed that while dose and infection are related, the relationship between dose and disease response is poor. Hence, infectivity (the ability of the virus to cause infection) increases with dose, but pathogenicity (the ability of the virus to cause disease) is not associated with dose. Dose-response, as median lethal dose, has been used to determine pathogenicity for WNV (Beasley et al., 2004; Frost et al., 2012) , but our study indicates that measures of disease, such as tissue tropism, would be more insightful.
Our study indicated crucial differences in the infection between high pathogenic and less pathogenic WNV variants. Table 4 and calculated by a hierarchical cluster analysis. The height represents the scaled distance at which each fusion of the clusters is made.
Mouse model for West Nile virus
Whereas all tested WNV variants appear to replicate efficiently in neural tissue, the pathogenic North American WNV had a markedly higher incidence of replication in other tissues, including blood vessel walls and connective tissues. Although extra-neural replication was also present in WNV-KUNV-infected mice, mainly in small focal lesions in the developing teeth, this was not a major feature of the infections. Therefore, we propose that the principal pathogenetic difference between pathogenic WNV (typified by WNV NY99 4132) and the Australian WNV variants is that the former are able to replicate more efficiently outside the CNS to establish systemic infections. A similar mechanism has been proposed to account for differences seen with mice of different immunological status (Samuel & Diamond, 2005; Samuel et al., 2006) . WNV replication in systemic tissues has been reported for severely immunocompromised human cases (Armah et al., 2007) . Whilst in itself systemic replication appeared to have a minor pathological effect in mice, it may allow faster and more extensive spread of virus, including increasing the number of entry portals into the CNS.
Our study indicated that WNV KUNV-MRM16 is the least pathogenic of the strains tested. It was obviously capable of infecting neural tissue, but seroconversion in healthy mice at the end of the trial indicated that most mice were able to overcome infection, including infection of the brain, as indicated by histopathology. The reasons for the low pathogenicity are not clear. It has been shown that laboratory passage influences glycosylation of the envelope protein (Adams et al., 1995) and this may have a significant influence on pathogenicity. WNV has been passaged under laboratory conditions; the exact history is not available for the strain used, but it may have undergone multiple passages in cells and suckling mice. The influence on morphological pathogenesis of envelope protein glycosylation and other molecular features should be investigated in the model described here, to shed light on the molecular determinants of pathotype.
The determinants of pathogenicity of WNV are probably principally immunologically mediated, as the manipulation of various immune pathways leads to altered pathogenicity (Diamond, 2009; Samuel et al., 2006) . One of the principal differences between pathogenic North American WNV and WNV-KUNV (and other less pathogenic WNV variants) is that the former is more capable of evading IFN-induced pathways (Daffis et al., 2011; Keller et al., 2006; Liu et al., 2005) . IFNs are generated by infected cells to signal to other cells that a viral infection is present, therefore inducing a range of defensive responses in neighbouring and distant cells. The IFN response can be activated within hours of infection, and can limit the replication and spread of virus within the host. Immunoglobulin responses are also critical to limiting the early viral spread, although they may take days to become effective (Diamond et al., 2003) . Our data, showing that the replication of WNV-KUNV is almost entirely restricted to the CNS, is consistent with this concept. The superior replication of WNV NY99 in non-neural cell types would indicate that inhibition of viral replication is not present to the same degree in mice infected with this virus.
The immune response of the CNS is different in several respects to that of the systemic tissues. The range of immune response options in the CNS is more limited, as cells of the adaptive immune system are not normally resident in the CNS and have to be mobilized from the blood via the blood-brain barrier under the control of chemokines. Hence, loss of chemokine function leads to greater susceptibility to WNV and prolonged infections (Bardina & Lim, 2012) . Our data show that WNV-KUNV is able to replicate efficiently in mouse CNS, implying that the CNS immune functions are not able to limit this virus with the efficiency that the systemic immune system can. It is likely that virus replicates in the CNS partly because it is a safe refuge from immune attack. However, the finding of viral antigen in the enteric nervous system may indicate that the pathogenesis of neural tropism is more complex. If neural tropism was only the result of the nervous system being a safe refuge from the immune system, then we would not expect significant replication in enteric neurons, which do not have an immunological barrier similar to that found in the brain.
Infections of the enteric nervous system could have been the principal reason for the intestinal stasis seen in many of the mice, in both this study and others (Kimura et al., 2010) . As the myenteric plexus is the coordinating centre of the gut, its dysfunction would lead to slowing and cessation of peristalsis, with stasis of ingesta. A large number of mice showed signs of intestinal dysfunction, i.e. hunched posture, abdominal swelling and accumulation of ingesta. However, intestinal dysfunction and its associated signs are not an observation of natural cases of flaviviruses in humans and horses.
In conclusion, our extended mouse model is a promising candidate for the study of pathogenicity and pathogenesis of WNV and possibly other flaviviruses. WNV variants cause a range of pathogenetic presentations in mice and these can be used to classify their disease-causing potential. A critical part of this mouse model is the measure and analysis of disease signs, histopathological lesions and antigen distribution in tissues. This allows mice to be euthanized prior to terminal disease, which is an animal welfare improvement as it avoids the use of lethality as a measure of pathogenicity. By maximizing the use of information from the mice, the model will help to advance our understanding of these important pathogens.
METHODS
Viruses. Five WNV group isolates were used in this study. The New York strain NY99 4132 (WNV NY99 ) was derived from an American crow and the inoculum used had undergone four passes in cell culture (Vero and C6/36 Aedes albopictus cell lines) (Audsley et al., 2011) . WNV-KUNV strain MRM16 (WNV KUNV-MRM16 ) was isolated originally from a C. annulirostris mosquito pool in 1960 (Doherty et al., 1963) , and had been passed in suckling mice and Vero cells.
WNV-KUNV strain Boort (WNV KUNV-Boort ) was isolated in 1984 from the spinal cord of a horse with neurological signs from southern Australia (Badman et al., 1984) . Mann et al., 2013) .
All final inoculum stock viruses were produced in Vero cells. Stock virus was diluted in PBS to the required dose in 0.1 ml. Virus stocks, inocula (as back-titration of highest concentration inocula) and terminal serum samples from challenged mice were titrated to determine virus content. Vero cells were grown in Gibco minimum essential media (Thermo Fisher Scientific) with 10 % FCS and plated out into flat-bottomed 96-well plates (Nunc). Tenfold dilutions (from 10 21 to 10
27
) were made in PBS in separate tubes and 0.1 ml of each sample dispensed per well (four replicates each). Plates were incubated at 37 uC for 5 days, then read for the presence of cytopathic effect and the titre calculated in TCID 50 per 0.1 ml.
Animals. All mice and experimental procedures were approved by the CSIRO-AAHL Animal Ethics Committee, and conducted according to the animal welfare principles outlined in the Australian code of practice for the care and use of animals for scientific purposes. Outbred Swiss mice [Arc(S)], of both sexes, were bred from breeder stock obtained from Animal Resources Centre (Canning Vale). At the time of challenge all the mice were 18-20 days old (6.7-14.3 g, mean 11.4 g) and had been weaned the day prior to challenge. The mice were housed in groups of five in standard rat cages, and provided with food and water ad libitum. During and after challenge the mice were kept at physical containment level 3. They were observed and the necessary husbandry conducted once a day during mid-morning.
Trial design. A total of 120 weaned mice were assigned randomly to 24 treatment groups (five mice per group) defined by virus and dose. To limit the groups to practically manageable numbers, dose series were decided according to previously published information (Beasley et al., 2004) : five for WNV NY99 (10 21 to 10 3 TCID 50 ) and the three horse strains (10 0 -10 4 TCID 50 ) and three for WNV KUNV-MRM16 (10 2 -10 4 TCID 50 ). One negative control group received PBS diluent only. A volume of 0.1 ml inoculum was injected into the abdominal cavity under light isoflurane (Isorrane; Baxter Healthcare) anaesthesia. Immediately after inoculation, the mice were assigned to cages (five per cage) by a predetermined random allocation scheme. The mice were observed for clinical signs and weighed daily until the termination of the trial at 14 days p.i. During periods of peak disease they were observed more frequently. For each mouse, the presence or absence of a standard set of disease signs was recorded (Table 4) . Mice with definite signs of illness were euthanized and samples taken. Mice were euthanized by cardiac exsanguination under deep anaesthesia [ketamine (Ketamil; Troy Ilium) 75 mg kg 21 and medetomidine (Domitor; Novartis) 1 mg kg 21 combination given by the intraperitoneal route], followed by cervical dislocation. Terminal blood samples were collected for serum. After skinning, the cranium, thorax and abdomen were opened and examined, and then the carcasses were fixed in neutral-buffered formalin for histological testing.
Histological procedures. Fixed mouse carcasses were placed into decalcifying solution (saturated EDTA in 10 % formalin) for up to 2 weeks prior to cutting them into transverse blocks for processing. Generally, six cross-sections of brain (from the olfactory bulbs to the medulla oblongata) and three sections of spinal cord (cervical, thoracic at the level of the heart, lumbar at the level of the kidneys) were examined for each mouse. Various other organs were examined, including structures of the head, lung, heart, spleen, kidney and intestine. The tissues were processed by routine histological methods, and sections of each were stained with haematoxylin and eosin to observe for lesions. Histological sections were stained by an immunohistochemistry method, for visualization of viral antigen. The primary antibody was a mouse mAb, 4G4, directed against the NS1 protein of Murray Valley encephalitis virus, a closely related flavivirus (Clark et al., 2007) . Sections on glass slides were dewaxed through xylene and a graded series of ethanol (100 to 0 %)/water. Antigens were retrieved by heating at 90 uC for 30 min in high pH buffer (DM828; Dako). Viral antigens were detected on a Shannon Sequenza immunostaining centre (Thermo Scientific), using the Animal Research kit (ARK K3954; Dako) according to the manufacturer's instructions. Primary antibody (4G4) was conjugated with biotin shortly prior to slide staining. The following were applied to the slides: 3 % hydrogen peroxidase (Chemsupply) for 5 min, avidin followed by biotin blocks (X0590; Dako) for 10 min each, conjugated primary antibody for 60 min, secondary streptavidin-HRP for 45 min and aminoethylcarbazone (AEC) chromagen (Dako AEC+ K3469; Dako) for 10 min. Tris buffer at pH 7.6 was used to wash between each step. The sections were then counterstained with LillieMayer haematoxylin containing 0.5 % haematoxylin Certistain (Australian Biostain) for 30 s and Scotts tap water, also for 30 s, and mounted with aqueous mountant (S3025; Dako).
Serology. Sera were assessed for viral antibody by indirect ELISA. In brief, Nunc Maxisorb plates were coated with gradient purified WNV-KUNV (strain MRM61C) diluted in carbonate buffer (pH 9.6) for 1 h at 37 uC. Coating and subsequent binding steps were followed by a four-cycle rinse with wash buffer (PBS+0.05 % Tween 20). Sera were assessed at a 1/100 dilution in wash buffer with added 1 % skim milk powder for an incubation period of 1 h at 37 uC. Bound antibody was reacted with an anti-mouse-HRP conjugate (115-035-146; Jackson) for 30 min at 37 uC. 3,39,5,59-Tetramethylbenzidine substrate (T0440; Sigma) was reacted for 7 min before addition of 1 M H 2 SO 4 . OD 450 was determined.
An analysis was conducted on the ELISA results to determine the cutoff value. The OD 450 values fell into two distinct clusters: All those in the negative group (PBS-inoculated), plus a large number of other mice that also survived to the termination, had OD 450 ,0.05. Fifteen mice that survived to the trial termination and nearly all mice that became ill had OD 450 .0.15, including the early cases of day 5 and 6 p.i. Only two mice at 14 days p.i. had OD 450 readings between these ranges (0.08 and 0.14). Therefore, for the purposes of analysis, a threshold OD 450 of 0.15 was used to distinguish uninfected from seroconverted mice. In this analysis, it was assumed that seroconversion indicated that active viral replication had occurred, rather than it being a reaction to the antigen injected into the peritoneum. In 15 mice that survived, with seroconversion, to the termination of the trial, four also had histopathological signs of mild meningoencephalitis, suggesting strongly that these cases had indeed become infected and had recovered.
Statistical procedures. For each mouse, a set of clinical, immunological and pathological metrics, either measured directly or scored, were recorded (Table 4) . These metrics were treated as a multivariate dataset and were analysed with the object to group each infected mouse into pathological types. A distance matrix was calculated using Gower's distance and this was used as input for an agglomerative, hierarchical cluster analysis, using Ward's linkage to assess inter-cluster dissimilarity. All data manipulations and analyses were undertaken using R 2.15.0 (http://cran.r-project.org/) with the cluster analysis done using the 'cluster' and 'stats' packages. Median mouse infectious doses for each of the viruses were calculated by the trimmed Spearman-Kärber method (Hamilton et al., 1977) , as implemented in the R package 'tsk' (version 1.1). Table 3 
